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A BS TR AC T
BACKGROUND
Combination antifungal therapy (am pho ter i cin B deoxycholate and flu cy to sine) is 
the recommended treatment for cryptococcal meningitis but has not been shown 
to reduce mortality, as compared with am pho ter i cin B alone. We performed a ran-
domized, controlled trial to determine whether combining flu cy to sine or high-dose 
flu con a zole with high-dose am pho ter i cin B improved survival at 14 and 70 days.
METHODS
We conducted a randomized, three-group, open-label trial of induction therapy for 
cryptococcal meningitis in patients with human immunodeficiency virus infection. 
All patients received am pho ter i cin B at a dose of 1 mg per kilogram of body weight per 
day; patients in group 1 were treated for 4 weeks, and those in groups 2 and 3 for 
2 weeks. Patients in group 2 concurrently received flu cy to sine at a dose of 100 mg per 
kilogram per day for 2 weeks, and those in group 3 concurrently received flu con a zole 
at a dose of 400 mg twice daily for 2 weeks.
RESULTS
A total of 299 patients were enrolled. Fewer deaths occurred by days 14 and 70 among 
patients receiving am pho ter i cin B and flu cy to sine than among those receiving am-
pho ter i cin B alone (15 vs. 25 deaths by day 14; hazard ratio, 0.57; 95% confidence 
interval [CI], 0.30 to 1.08; unadjusted P = 0.08; and 30 vs. 44 deaths by day 70; hazard 
ratio, 0.61; 95% CI, 0.39 to 0.97; unadjusted P = 0.04). Combination therapy with flu con-
a zole had no significant effect on survival, as compared with monotherapy (hazard 
ratio for death by 14 days, 0.78; 95% CI, 0.44 to 1.41; P = 0.42; hazard ratio for death 
by 70 days, 0.71; 95% CI, 0.45 to 1.11; P = 0.13). Am pho ter i cin B plus flu cy to sine was 
associated with significantly increased rates of yeast clearance from cerebrospinal 
fluid (−0.42 log10 colony-forming units [CFU] per milliliter per day vs. −0.31 and 
−0.32 log10 CFU per milliliter per day in groups 1 and 3, respectively; P<0.001 for 
both comparisons). Rates of adverse events were similar in all groups, although 
neutropenia was more frequent in patients receiving a combination therapy.
CONCLUSIONS
Am pho ter i cin B plus flu cy to sine, as compared with am pho ter i cin B alone, is associated 
with improved survival among patients with cryptococcal meningitis. A survival ben-
efit of am pho ter i cin B plus flu con a zole was not found. (Funded by the Wellcome Trust 
and the British Infection Society; Controlled-Trials.com number, ISRCTN95123928.)
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There are approximately 1 million cases of cryptococcal meningitis annually and 625,000 deaths.1 Treatment guidelines 
recommend induction therapy with am pho ter i cin 
B deoxycholate (0.7 to 1 mg per kilogram of body 
weight per day) and flu cy to sine (100 mg per kilo-
gram per day).2 However, this treatment has not 
been shown to reduce mortality, as compared 
with am pho ter i cin B monotherapy.2,3 Flu cy to sine is 
frequently unavailable where the disease burden is 
greatest, and concerns about cost and side effects 
have limited its use in resource-poor settings.4
Flu con a zole is readily available, is associated 
with low rates of adverse events, and has good 
penetration into cerebrospinal fluid (CSF), but it 
is associated with poor outcomes when used as 
monotherapy for cryptococcal meningitis.2 Its 
safety profile, low cost, and availability make it 
an attractive alternative to flu cy to sine for combi-
nation therapy with am pho ter i cin B, and it is rec-
ommended as an alternative in the guidelines.2 
However, when this combination was used in 
conventional doses (am pho ter i cin B at a dose of 
0.7 mg per kilogram per day and flu con a zole at 
a dose of 400 mg per day), it did not improve the 
rate of yeast clearance from the CSF, in a study 
not powered for clinical end points.5 Increased 
doses of am pho ter i cin B (1 mg per kilogram per 
day) and flu con a zole (800 to 1200 mg per day) 
independently result in improved rates of yeast 
clearance.6,7 To our knowledge, these increased 
doses have not been tested in combination.8
In Asia, many patients receive treatment with 
am pho ter i cin B monotherapy for 2 to 4 weeks, 
followed by flu con a zole at a dose of 400 mg per 
day until the end of week 10. In view of the high 
mortality (55% in Asia and 70% in Africa1), we 
performed an open-label, randomized, controlled 
trial to determine whether combination therapy 
with either am pho ter i cin B (at a dose of 1 mg per 
kilogram per day) and flu cy to sine (at a dose of 
100 mg per kilogram per day) or am pho ter i cin B 
and flu con a zole (at a dose of 400 mg twice daily) 
offered a survival advantage, as compared with 
am pho ter i cin B alone (at a dose of 1 mg per ki-
logram per day).
ME THODS
STUDY DESIGN AND PARTICIPANTS
The study was designed as a randomized, three-
group trial of induction therapy for cryptococcal 
meningitis in patients with human immunodefi-
ciency virus (HIV) infection. Patients were re-
cruited at the Hospital for Tropical Diseases, Ho 
Chi Minh City, Vietnam. Eligible patients had HIV 
infection, were more than 14 years old, and had 
symptoms and signs consistent with cryptococcal 
meningitis and one or more of the following: 
positive India ink staining of the CSF, a positive test 
for CSF cryptococcal-antigen, a positive CSF or 
blood culture for Cryptococcus neoformans, or a pos-
itive test for blood cryptococcal antigen (titer of 
>1:10). Patients could have normal or mildly ele-
vated creatinine levels. Patients were excluded if 
they had received antifungal therapy for more than 
3 days, had had cryptococcosis, were pregnant, 
had renal or liver failure, were receiving rifampin, 
or did not provide written informed consent. For 
details of the study design, see the study proto-
col, available with the full text of this article at 
NEJM.org.
STUDY OVERSIGHT
The study was approved by the institutional re-
view boards at the Hospital for Tropical Diseases 
and the Liverpool School of Tropical Medicine. 
Written informed consent was obtained from all 
patients or from a relative if the patient could not 
provide consent. An independent data and safety 
monitoring committee provided oversight. Inter-
im analyses were performed after 12 months and 
after 200 patients had completed follow-up. All 
authors vouch for the completeness and accuracy 
of the data presented. Cipla and Ranbaxy Labora-
tories provided am pho ter i cin B and flu con a zole, 
respectively, at a reduced cost. Flu cy to sine (Valeant 
Pharmaceuticals France) was purchased at full cost 
from a pharmacy. None of the drug manufacturers 
or suppliers had any role in the study design, data 
accrual and analysis, or manuscript preparation.
LABORATORY INVESTIGATIONS
Lumbar punctures were performed weekly for the 
first month of treatment and as clinically indi-
cated. Quantitative yeast counts were determined 
for all specimens.5 All strains were confirmed as 
cryptococcus species. For details, see the Supple-
mentary Appendix, available at NEJM.org.
TREATMENT
Patients were randomly assigned to one of three 
induction treatments. Patients in group 1 received 
intravenous am pho ter i cin B at a dose of 1 mg per 
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kilogram per day for 4 weeks, followed by oral flu-
con a zole at a dose of 400 mg per day for 6 weeks, 
which was in line with local practice at the incep-
tion of the study. Patients in group 2 received am-
pho ter i cin B deoxycholate at a dose of 1 mg per 
kilogram per day for 2 weeks, combined with oral 
flu cy to sine at a dose of 100 mg per kilogram per 
day in three to four divided doses. These patients 
then received flu con a zole at a dose of 400 mg per 
day for 8 weeks. The patients in group 3 received 
am pho ter i cin B deoxycholate at a dose of 1 mg per 
kilogram per day, combined with oral flu con a-
zole at a dose of 400 mg twice daily, for 2 weeks. 
These patients then received flu con a zole at a dose 
of 400 mg per day for 8 weeks. Details regarding 
drug administration are provided in the Supple-
mentary Appendix.
A computer-generated sequence of random 
numbers was used to assign patients to treatment 
groups (for details, see the Supplementary Ap-
pendix). The attending physicians were respon-
sible for enrolling participants and ensuring that 
the correct study drug was given. Daily monitor-
ing of all inpatients by a member of the study 
team ensured uniform management and accurate 
recording of data. Increased intracranial pressure 
299 Were enrolled and underwent
randomization
375 Patients were assessed for eligibility
76 Were excluded
20 Had received antifungal therapy for >3 days
5 Were HIV-seronegative
2 Had cryptococcosis previously
22 Were receiving rifampin
10 Declined to participate
8 Had abnormal liver-enzyme levels
9 Had other reasons
100 Were assigned to receive
amphotericin B, 1 mg/kg/day,
for 4 wk
99 Received assigned treatment
1 Did not have cryptococcal
meningitis and did not receive
assigned treatment
99 Were assigned to receive
amphotericin B,
1 mg/kg/day, and fluconazole,
400 mg twice daily, for 2 wk
99 Received assigned treatment
11 Were excluded from per-
protocol analysis
8 Did not complete
randomized treatment
2 Were receiving rifampin
at study entry
1 Had received antifungal
therapy for  >3 days
before randomization
2 Were lost to follow-up
99 Were included in intention-to-
treat analysis
87 Were included in per-protocol
analysis
99 Were included in intention-to-
treat analysis
88 Were included in per-protocol
analysis
100 Were assigned to receive
amphotericin B,
1 mg/kg/day, and flucytosine,
100 mg/kg/day, for 2 wk
100 Received assigned treatment
8 Were excluded from per-
protocol analysis
7 Did not complete
randomized treatment 
1 Was receiving rifampin
at study entry
4 Were lost to follow-up
12 Were excluded from per-
protocol analysis
11 Did not complete
randomized treatment
1 Was receiving rifampin
at study entry
1 Was lost to follow-up
100 Were included in intention-to-
treat analysis
92 Were included in per-protocol
analysis
Figure 1. Study Enrollment, Treatment Assignments, and Analysis Populations.
Of 375 patients who underwent assessment, 299 were enrolled in the study. One patient, who underwent random-
ization but did not have cryptococcal meningitis, did not receive the assigned treatment and was excluded from the 
intention-to-treat analysis.
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was treated with therapeutic lumbar puncture. 
After discharge, patients were assessed monthly 
until 6 months after randomization.
All patients received Pneumocystis jirovecii pneu-
monia prophylaxis (co-trimoxazole at a dose of 
960 mg per day). Antiretroviral therapy (ART) was 
prescribed according to national guidelines. Pa-
tients already receiving ART at the time of diag-
nosis continued the therapy. All patients who had 
not received ART were referred to the hospital ART 
clinic. The decision to initiate ART depended on 
the attending physician’s assessment and the pa-
tient’s preference and was independent of study 
participation.
ASSESSMENT OF OUTCOMES
The prespecified coprimary outcomes were all-
cause mortality in the first 14 and 70 days after 
randomization. Prespecified secondary outcomes 
included mortality at 6 months, disability status 
at 70 days and at 6 months (defined as 182 days), 
changes in CSF fungal counts in the first 2 weeks 
after randomization, time to CSF sterilization, and 
adverse events during the first 10 weeks of the 
study. Disability status was assessed with the use 
of two simple questions (“Do you require help 
from anybody for everyday activities [e.g., eating, 
drinking, washing, brushing teeth, and going to 
the toilet]?” and “Has the illness left you with any 
Table 1. Baseline Characteristics of the Study Participants.*
Characteristic
Group 1,  
Amphotericin B 
(N = 99)
Group 2,  
Amphotericin B  
and Flucytosine
(N = 100)
Group 3,  
Amphotericin B  
and Fluconazole
(N = 99)
Age — yr†
Median 28 28 27
Interquartile range 25–31 25–33 24–31
Male sex — no. (%) 81 (82) 80 (80) 84 (85)
Intravenous drug use — no./total no. (%) 51/90 (57) 49/94 (52) 53/97 (55)
Duration of symptoms — days‡
Median 15 14 12
Interquartile range 7–22 8–18 7–20
Headache — no./total no. (%) 95/97 (98) 99/99 (100) 98/99 (99)
Fever — no./total no. (%) 75/97 (77) 75/98 (77) 72/98 (73)
Neck stiffness — no./total no. (%) 66/91 (73) 64/91 (70) 66/95 (69)
Seizure — no./total no. (%) 9/94 (10) 9/98 (9) 2/98 (2)
Glasgow Coma Scale score — no./total no. (%)§
15 66/97 (68) 67/99 (68) 78/98 (80)
11–14 21/97 (22) 24/99 (24) 15/98 (15)
≤10 10/97 (10) 8/99 (8) 5/98 (5)
Cranial-nerve palsy — no./total no. (%) 27/97 (28) 22/98 (22) 18/98 (18)
Papilledema — no./total no. (%) 18/85 (21) 19/89 (21) 17/93 (18)
CSF opening pressure >18 cm of CSF — no./ 
total no. (%)
56/83 (67) 61/80 (76) 55/81 (68)
CSF white-cell count — cells/ml¶
Median 33 26 24
Interquartile range 7–76 8–61 7–83
CSF glucose level — mmol/liter‖
Median 2.21 2.30 2.34
Interquartile range 1.50–3.00 1.70–2.98 1.70–2.99
Plasma glucose level — mmol/liter**
Median 5.69 5.90 5.43
Interquartile range 4.84–6.50 4.88–6.90 4.80–6.20
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other problems?”) and the modified Rankin scale 
(scores range from 0 [no symptoms at all] to 
6 [death]) and was classified as good (i.e., no dis-
ability), intermediate, severe, or death, as de-
scribed elsewhere.9
STATISTICAL ANALYSIS
The trial was designed to detect, with 80% pow-
er, a difference in mortality of 45% versus 25% at 
10 weeks between the group that received am pho-
ter i cin B monotherapy and each group that received 
combination treatment, at a two-sided 5% signifi-
cance level. The planned sample was 297 patients.
The primary aims of this study were the com-
parisons of survival at 14 and 70 days of the two 
combination treatments, respectively, with am-
pho ter i cin B monotherapy. The time to death 
was compared between treatment groups at day 
14, day 70, and day 182 with the use of a Cox 
regression model, with treatment indicators as 
the only covariates. Potential heterogeneity of the 
treatment effect depending on covariates was 
tested with the use of a likelihood-ratio test for 
interaction. For mortality at day 70 and at day 
182, we also performed an adjusted Cox regres-
sion analysis with the following prespecified co-
variates (in addition to randomized treatment): 
age, sex, log-quantitative fungal count, Glasgow 
Coma Scale score (15 vs. <15, with scores rang-
ing from 3 to 15, and lower scores indicating 
reduced levels of consciousness), CD4 cell count, 
hemoglobin level, serum sodium level, log CSF 
white-cell count, and CSF opening pressure.
The proportions of patients with good disabil-
ity status on day 70 and on day 182 were com-
pared among groups with the use of a logistic-
regression model. The decline in the log CSF 
quantitative fungal count in the first 2 weeks was 
estimated by means of longitudinal measure-
ments during that period and a linear mixed-
effects model with an interaction term between 
the treatment group and study day. Time to 
fungal clearance was estimated with a cause-
specific Cox regression model adjusted for base-
line fungal count. The multivariate Cox regres-
sion analyses and the analysis of disability status 
were based on multiple imputation of missing 
covariates and disability outcomes.
The study had four prespecified primary anal-
yses. There is no consensus in the literature re-
Table 1. (Continued.)
Characteristic
Group 1,  
Amphotericin B 
(N = 99)
Group 2,  
Amphotericin B  
and Flucytosine
(N = 100)
Group 3,  
Amphotericin B  
and Fluconazole
(N = 99)
CSF yeast count — log10 CFU/ml††
Median 5.91 5.81 5.74
Interquartile range 5.49–6.48 4.74–6.15 4.80–6.34
CD4 count — cells/mm3‡‡
Median 18 17 14
Interquartile range 8–37 9–28 8–41
Creatinine — μmol/liter§§
Median 72.0 73.0 70.4
Interquartile range 61.0–93.5 60.0–86.0 61.1–88.5
* There were no significant between-group differences at baseline, with the exception of CSF yeast count (P = 0.03 by 
the Kruskal–Wallis test). For additional details, see Table S1 in the Supplementary Appendix. CFU denotes colony-
forming units, and CSF cerebrospinal fluid. To convert the values for glucose to milligrams per deciliter, divide by 
0.05551. To convert the values for creatinine to milligrams per deciliter, divide by 88.4.
† Data were missing for 1 patient in group 3.
‡ Data were missing for 14 patients in group 1, for 6 in group 2, and for 8 in group 3.
§ Scores on the Glasgow Coma Scale range from 3 to 15, with lower scores indicating reduced levels of consciousness.
¶ Data were missing for 10 patients in group 1, for 12 in group 2, and for 12 in group 3.
‖  Data were missing for 6 patients in group 2, for 4 in group 2, and for 6 in group 3. 
** Data were missing for 8 patients in group 1, for 8 in group 2, and for 6 in group 3.
†† Data were missing for 22 patients in group 1, for 20 in group 2, and for 20 in group 3.
‡‡ Data were missing for 28 patients in group 1, for 26 in group 2, and for 26 in group 3.
§§ Data were missing for 8 patients in group 1, for 3 in group 2, and for 4 in group 3. 
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garding whether statistical adjustment is needed 
for trials that use a common control group, be-
cause the addition of a group to a trial enhances 
rather than diminishes informativeness.10,11 Schulz 
and Grimes argue that adjusting the analysis of 
related end points for multiple testing is not man-
datory.12 Our trial was not powered to account 
for multiplicity adjustment, and we report unad-
justed P values for all comparisons. We present 
the Bonferroni-corrected P values as a supple-
mentary analysis.
The primary analysis was performed with data 
from the intention-to-treat population, which in-
cluded all patients who had undergone random-
ization. The analysis of mortality at 70 days was 
also performed with data from the per-protocol 
population, which excluded patients with major 
protocol violations. All analyses were performed 
Table 2. Primary and Key Secondary Outcomes.*
Outcome
Group 1,  
Amphotericin B
(N = 99)
Group 2,  
Amphotericin B  
and Flucytosine
(N = 100)
Group 3,  
Amphotericin B  
and Fluconazole
(N = 99)
Coprimary outcomes
Death by day 14
No. of deaths 25 15 20
Probability of survival (95% CI) 0.75 (0.67 to 0.84) 0.85 (0.78 to 0.92) 0.80 (0.73 to 0.88)
Death by day 70‡
No. of deaths 44 30 33
Probability of survival (95% CI) 0.56 (0.47 to 0.66) 0.69 (0.61 to 0.79) 0.67 (0.58 to 0.77)
Secondary outcomes
Death by day 70 in the per-protocol population
No. of deaths/no. of patients included in analysis 37/87 26/92 27/88
Probability of survival (95% CI) 0.58 (0.48 to 0.69) 0.71 (0.63 to 0.81) 0.69 (0.60 to 0.80)
Death by day 182§
No. of deaths 53 34 45
Probability of survival (95% CI) 0.46 (0.37 to 0.57) 0.65 (0.56 to 0.75) 0.54 (0.45 to 0.65)
Estimated change in CSF fungal count in first 14 days (95% CI) 
— log10 CFU/ml/day
−0.31 (−0.34 to −0.29) −0.42 (−0.44 to −0.40) −0.32 (−0.34 to −0.29)
CSF fungal clearance
No. of patients with documented clearance 52 74 63
Clearance rate per person-wk of follow-up (95% CI) 0.17 (0.13 to 0.23) 0.39 (0.31 to 0.50) 0.26 (0.20 to 0.34)
* Reported results are for the intention-to-treat population unless otherwise specified and were not adjusted for baseline covariates or multiple 
comparisons, except for time to CSF fungal clearance, which was adjusted for baseline fungal count. In the coprimary comparisons for death by 
14 days and death by 70 days in group 2 versus group 1 and in group 3 versus group 1, conservative Bonferroni multiplicity adjustment 
would require doubling of the P values (adjustment for multiple primary end points) or would require the P value to be four times as large 
(adjustment for multiple primary end points and for multiple comparisons of the combination therapies versus a common control group). 
For disability outcomes, see Table S2 in the Supplementary Appendix.
† Hazard ratios are shown for all outcomes except for the estimated change in CSF fungal count, for which the between-group difference in the 
estimated change is shown.
‡ When hazard ratios for death by day 70 were adjusted for baseline covariates, the results were as follows: for group 2 versus group 1, the 
hazard ratio was 0.62 (95% CI, 0.38 to 0.996), P = 0.048; for group 3 versus group 1, the hazard ratio was 0.94 (95% CI, 0.58 to 1.51), P = 0.80; 
and for group 2 versus group 3, the hazard ratio was 0.66 (95% CI, 0.39 to 1.10), P = 0.11.
§ When hazard ratios for death by day 182 were adjusted for baseline covariates, the results were as follows: for group 2 versus group 1, the 
hazard ratio was 0.56 (95% CI, 0.36 to 0.87), P = 0.01; for group 3 versus group 1, the hazard ratio was 1.01 (95% CI, 0.66 to 1.53), P = 0.97; 
and for group 2 versus group 3, the hazard ratio was 0.55 (95% CI, 0.35 to 0.88), P = 0.01.
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with the use of R software, version 2.13.1,13 and 
the R software packages mice, version 2.8,14 and 
multcomp, version 1.2-5.15
R ESULT S
STUDY POPULATION
Figure 1 shows the numbers of patients who were 
enrolled, assigned to a treatment group, and in-
cluded in the intention-to-treat and per-protocol 
analyses. A total of 299 patients were randomly 
assigned to induction antifungal therapy between 
April 2004 and September 2010. One patient, 
who underwent randomization but did not have 
cryptococcal meningitis, was excluded from the 
intention-to-treat analysis. An additional 31 pa-
tients were excluded from the per-protocol analysis: 
26 patients withdrew before the completion of the 
randomly assigned treatment (11, 7, and 8 pa-
tients from groups 1, 2, and 3, respectively), 4 were 
subsequently found to be taking rifampin at ran-
domization, and 1 had received antifungal therapy 
for more than 3 days. Survival status at 6 months 
was missing for 7 patients.
Baseline characteristics of the patients are 
shown in Table 1. C. neoformans was cultured from 
the CSF of 291 of 298 patients (97.7%) and 
from the blood of 122 of 168 patients (72.6%). 
All infections were C. neoformans var. grubii mo-
lecular type VNI. Seven patients had mildly ele-
vated creatinine levels (range, 145 to 188 μmol 
per liter).
PRIMARY OUTCOMES
Key outcomes are summarized in Table 2. By day 
70, a total of 44 patients treated with am pho ter i-
cin B monotherapy had died, as compared with 
30 patients treated with am pho ter i cin B and flu-
cy to sine and 33 patients treated with am pho ter i-
cin B and flu con a zole (Fig. 2A). Treatment with 
Hazard Ratio or Difference in Estimated Change (95% CI)†
Group 2 vs. Group 1 P Value Group 3 vs. Group 1 P Value Group 2 vs. Group 3 P Value
0.57 (0.30 to 1.08) 0.08 0.78 (0.44 to 1.41) 0.42 0.72 (0.37 to 1.41) 0.34
0.61 (0.39 to 0.97) 0.04 0.71 (0.45 to 1.11) 0.13 0.87 (0.53 to 1.42) 0.57
0.60 (0.36 to 0.99) 0.04 0.68 (0.41 to 1.11) 0.12 0.88 (0.52 to 1.51) 0.65
0.56 (0.36 to 0.86) 0.01 0.78 (0.53 to 1.16) 0.23 0.72 (0.46 to 1.12) 0.14
−0.10 (−0.14 to −0.07) <0.001 0.00 (−0.04 to 0.03) 0.83 −0.10 (−0.14 to −0.07) <0.001
3.18 (2.17 to 4.66) <0.001 1.39 (0.94 to 2.07) 0.10 2.29 (1.59 to 3.29) <0.001
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am pho ter i cin B and flu cy to sine was associated 
with a significantly reduced hazard of death by 
day 70 in the intention-to-treat analysis (hazard 
ratio, 0.61; 95% confidence interval [CI], 0.39 to 
0.97; P = 0.04); this benefit was maintained in the 
per-protocol analysis and after adjustment for pre-
defined baseline covariates. Fewer patients re-
ceiving combination therapy with high-dose flu-
con a zole died, as compared with those treated with 
am pho ter i cin B monotherapy, but this finding 
was not significant (hazard ratio, 0.71; 95% CI, 
0.45 to 1.11; P = 0.13).
No evidence of heterogeneity in treatment ef-
fects was detected for CD4 count, intravenous 
drug use, baseline log fungal count, or score on 
the Glasgow Coma Scale (P>0.10 for all tests). 
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Figure 2. Kaplan–Meier Survival Estimates and Cerebrospinal Fluid (CSF) Fungal Counts, According to Treatment 
Group.
Panel A shows the Kaplan–Meier survival estimates according to treatment group. For mortality at 70 days, P = 0.04 
for the comparison of am pho ter i cin B plus flu cy to sine with am pho ter i cin B monotherapy, and P = 0.13 for the com-
parison of am pho ter i cin B plus flu con a zole with am pho ter i cin B monotherapy. Panel B shows the CSF quantitative 
fungal counts over time, according to treatment group. Study day 1 corresponds to the day of randomization. All re-
corded CSF quantitative counts are shown, including those in patients who subsequently died. CSF fungal decline in 
the first 14 days and time to clearance were significantly faster among patients receiving am pho ter i cin B plus flu cy-
to sine than among patients in the other treatment groups (P<0.001 for all comparisons). In each graph, gray lines 
indicate data for individual patients; the red line indicates a loess scatterplot smoother calculated with the use of  
local regression. CFU denotes colony-forming units.
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Between-group differences in survival rates at day 
14 were not significant (15 deaths in group 2 vs. 
25 deaths in group 1; P = 0.08).
SECONDARY OUTCOMES
The survival benefit seen for patients receiving 
am pho ter i cin B and flu cy to sine, as compared with 
those receiving am pho ter i cin B monotherapy, 
was more marked at 6 months (hazard ratio, 0.56; 
95% CI, 0.36 to 0.86; P = 0.01). Treatment with 
am pho ter i cin B and flu con a zole did not confer a 
survival advantage, as compared with monother-
apy. There was no significant difference in sur-
vival between the two combination-treatment 
groups. However, after adjustment for baseline 
covariates, combination therapy with flu cy to sine 
was associated with a reduced hazard of death, as 
compared with am pho ter i cin B alone (hazard ra-
tio, 0.56; 95% CI, 0.36 to 0.87; P = 0.01) or with 
am pho ter i cin B plus flu con a zole (hazard ratio, 
0.55; 95% CI, 0.35 to 0.88; P = 0.01). The multi-
variable Cox regression identified the following 
independent predictors of 6-month survival: 
baseline fungal count (hazard ratio for each in-
crease of 1 log10 colony-forming unit [CFU] per 
milliliter, 1.33; 95% CI, 1.08 to 1.65; P = 0.01) and 
a score on the Glasgow Coma Scale of less than 
15 (hazard ratio, 2.30; 95% CI, 1.57 to 3.36; 
P<0.001).
Patients receiving am pho ter i cin B and flu cy to-
sine had a significantly higher chance of being free 
of disability at 6 months, as compared with those 
receiving monotherapy (odds ratio, 2.01; 95% CI, 
1.04 to 3.88; P = 0.04). At day 70, a visual deficit was 
present in 16 of 46 assessed patients treated with 
am pho ter i cin B, as compared with 9 of 54 patients 
treated with am pho ter i cin B and flu cy to sine and 
8 of 48 patients treated with am pho ter i cin B and 
high-dose flu con a zole. A total of 8 patients had 
complete visual loss (no light perception).
The time to fungal clearance was significantly 
shorter in patients receiving am pho ter i cin B plus 
flu cy to sine than in those receiving am pho ter i cin 
B alone or in combination with flu con a zole, with 
more rapid rates of decline in the colony count 
(−0.42 log10 CFU per day vs. −0.31 log10 CFU per 
day and −0.32 log10 CFU per day, respectively; 
P<0.001 for both comparisons) (Fig. 2B).
EFFECT OF ANTIRETROVIRAL THERAPY
A total of 89 patients were receiving or started 
receiving ART during the 6-month follow-up: 27 
patients in the group receiving am pho ter i cin B 
alone, 32 in the group receiving am pho ter i cin B 
plus flu cy to sine, and 30 in the group receiving 
am pho ter i cin B plus flu con a zole. A total of 2, 5, 
and 3 patients in the three groups, respectively, 
were receiving ART at study entry; 2, 2, and 4 pa-
tients started receiving ART within 2 weeks after 
randomization; and 17, 15, and 17 patients started 
receiving ART between day 14 and day 70. Be-
cause ART was started after enrollment for most 
patients and was conditional on survival, this 
study cannot determine whether ART improved 
survival, although studies to assess this effect are 
under way.
ADVERSE EVENTS
Adverse events occurred with similar frequency 
among all the treatment groups (Table 3). The 
most frequent adverse events were anemia, hypo-
kalemia, elevated aminotransferase levels, neu-
tropenia, hypercreatinemia, and opportunistic 
infection. Neutropenia was more frequent among 
patients receiving am pho ter i cin B with either flu-
cy to sine or flu con a zole than among those receiv-
ing am pho ter i cin B monotherapy (34% and 32%, 
respectively, vs. 19%; P = 0.04 for overall compar-
ison). Fewer patients had severe anemia in the 
group receiving am pho ter i cin B with flu con a zole 
(29% of patients) than in the group receiving am-
pho ter i cin B monotherapy (46%) and the group 
receiving am pho ter i cin B with flu cy to sine (35%). 
Modification or interruption of treatment with 
the study drug occurred in eight patients in each 
group.
DISCUSSION
Our study population was characterized by high 
CSF fungal burdens and a high proportion of pa-
tients (28%) with a Glasgow Coma Scale score of 
less than 15 at presentation, which are variables 
that are recognized to be important predictors of 
a poor outcome.3,16-22 The results of this study sug-
gest that in such patient populations, combination 
therapy with am pho ter i cin B and flu cy to sine is 
associated with improved survival, as compared 
with am pho ter i cin B monotherapy. The survival 
benefit was apparent 10 weeks after randomiza-
tion and was sustained for at least 6 months. More-
over, am pho ter i cin B plus flu cy to sine was associ-
ated with a higher likelihood of survival without 
disability than was am pho ter i cin B monotherapy. 
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Our primary comparisons did not account for mul-
tiplicity. As noted above, there is no agreement on 
whether such an adjustment is mandatory or even 
helpful.
We did not find a significant difference in sur-
vival between patients receiving am pho ter i cin B 
combined with high-dose flu con a zole and those 
receiving am pho ter i cin B monotherapy, although 
fewer deaths had occurred in the former group 
at 10 weeks.
The comparison between combination treat-
ments was secondary and did not reach statisti-
cal significance for most of the outcomes. How-
ever, in an exploratory comparison of survival at 
Table 3. Adverse Events.*
Event
Group 1,  
Amphotericin B
(N = 99)
Group 2,  
Amphotericin B
 and Flucytosine
(N = 100)
Group 3,  
Amphotericin B  
and Fluconazole
(N = 99) P Value†
Any event
At least one event — no. of patients (%) 82 (83) 85 (85) 85 (86) 0.85
No. of events 338 376 362
Hypokalemia — no. of patients (%)
All grades 54 (55) 56 (56) 54 (55) 0.98
Grades 3 and 4 20 (20) 22 (22) 13 (13) 0.24
Anemia — no. of patients (%)
All grades 62 (63) 63 (63) 57 (58) 0.71
Grades 3 and 4 46 (46) 35 (35) 29 (29) 0.04
Neutropenia — no. of patients (%)
All grades 19 (19) 34 (34) 32 (32) 0.04
Grades 3 and 4 2 (2) 9 (9) 9 (9) 0.07
Thrombocytopenia — no. of patients (%)
All grades 8 (8) 15 (15) 11 (11) 0.32
Grades 3 and 4 2 (2) 4 (4) 3 (3) 0.91
Rigor — no. of patients (%) 13 (13) 7 (7) 6 (6) 0.18
Opportunistic infection — no. of patients (%) 32 (32) 32 (32) 28 (28) 0.79
Rash — no. of patients (%) 5 (5) 7 (7) 5 (5) 0.86
New neurologic sign or symptom — no. of  
patients (%)
11 (11) 12 (12) 10 (10) 0.97
Seizure — no. of patients (%) 2 (2) 0 2 (2) 0.4
Elevated aminotransferase level — no. of  
patients (%)
All grades 38 (38) 44 (44) 42 (42) 0.72
Grades 3 and 4 11 (11) 6 (6) 14 (14) 0.14
Hyponatremia — no. of patients (%)
All grades 28 (28) 33 (33) 33 (33) 0.71
Grades 3 and 4 3 (3) 8 (8) 9 (9) 0.19
Hypercreatinemia — no. of patients (%)
All grades 34 (34) 41 (41) 46 (46) 0.22
Grades 3 and 4 2 (2) 2 (2) 2 (2) 1.00
Other — no. of patients (%)‡ 28 (28) 23 (23) 31 (31) 0.41
* All opportunistic infections and all events of grade 3 or 4 were classified as severe adverse events. For details, see Table 
S3 in the Supplementary Appendix.
† P values correspond to overall comparisons among the three groups with the use of Fisher’s exact test.
‡ Other adverse events occurred with a frequency of 0.3%, except nausea and vomiting (in 2.7% of all patients), sepsis 
(in 1.7%), and thrombophlebitis, hematemesis, diarrhea, and urinary retention (each in 0.7%).
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6 months that was adjusted for predefined base-
line factors, mortality was significantly higher 
among patients receiving am pho ter i cin B plus 
flu con a zole than among those receiving am pho-
ter i cin B plus flu cy to sine and did not differ sig-
nificantly from mortality among those treated 
with am pho ter i cin B monotherapy.
The survival benefit with am pho ter i cin B plus 
flu cy to sine that we observed in this study is in 
contrast to the results of a trial in North Amer-
ica.3 However, that study analyzed the effect of 
combination therapy at 2 weeks, included few 
patients with impaired consciousness, had a low 
overall death rate, and may not have had suffi-
cient power to show a survival effect. The sur-
vival benefit seen in our study is biologically 
plausible, being associated with significantly in-
creased rates of yeast clearance. These clearance 
data are consistent with smaller studies showing 
that flu cy to sine combined with am pho ter i cin B 
resulted in faster CSF yeast clearance than did 
am pho ter i cin B monotherapy or am pho ter i cin B 
plus fluconazole at a daily dose of 400 mg (i.e., 
a lower dose than was used in our study). A 
subsequent analysis of raw data collated from 
randomized, controlled trials and cohorts has 
suggested that the rate of fungal clearance from 
CSF is associated with the outcome.5,6,16 Converse-
ly, a recent study from South Africa did not show 
a significant difference in rates of CSF yeast clear-
ance between am pho ter i cin B plus flu cy to sine and 
am pho ter i cin B plus flu con a zole, but the study 
was limited by its small size and the lower fungal 
burden in the patients, as compared with the 
patients in our study.23 The association among 
antifungal-treatment combination, rate of clear-
ance of yeast from CSF, and mortality shown in 
our study is evidence that optimizing antifungal 
therapy is an important factor in improving out-
comes of cryptococcal meningitis. The rate of de-
cline of CSF yeast counts is a potential marker of 
survival in the evaluation of antifungal-treatment 
regimens, although the usefulness of measuring 
rates of fungal decline in the treatment of indi-
vidual patients is not clear. However, our study 
shows the feasibility of designing trials of treat-
ment for cryptococcal meningitis that are powered 
to assess mortality end points, and such studies 
seem appropriate for a disease with high mortality.
We found that a difference in antifungal ther-
apy during the first 2 weeks of a 10-week treatment 
was associated with a survival benefit at 6 months. 
Between 10 weeks and 6 months, 4 additional 
deaths occurred in patients receiving am pho ter i-
cin B plus flu cy to sine, versus 9 and 12 deaths in 
patients receiving am pho ter i cin B alone and those 
receiving am pho ter i cin B plus flu con a zole, re-
spectively. The causes of death in these patients 
were unclear, since many patients had returned 
to their home provinces. The lower death rate 
among patients receiving flu cy to sine, as com-
pared with the rate among those receiving am-
pho ter i cin B monotherapy, may have been due to 
lower rates of disability in these patients, which 
protected them from further complications, or 
lower rates of disease relapse, an association that 
has been previously identified.24,25
In conclusion, the results of this study sug-
gest that initial combination therapy with am pho-
ter i cin B and flu cy to sine for 2 weeks in our setting 
was associated with reduced mortality among pa-
tients with HIV-associated cryptococcal menin-
gitis, as compared with 4 weeks of am pho ter i cin B 
monotherapy. Combination therapy with flu con a-
zole for 2 weeks was not found to offer a benefit. 
Improving access to flu cy to sine has the potential 
to reduce the number of deaths from this disease.
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